News Search Results

Baystate is the only site in the western Massachusetts area participating in an international clinical trial testing whether statins can reduce the risk of heart disease in people with HIV infection, the REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) study.

Breast cancer risk and environmental exposure to common chemicals found in cosmetics and household products will be the focus of a five-year grant - expected to total $3.5 million - to a consortium of scientists at Baystate Medical Center, the Pioneer Valley Life Sciences Institute (PVLSI) and the Rays of Hope Center for Breast Cancer Research.

Pediatrician and researcher Sarah Goff, MD has received a national grant to study factors contributing to high quality pediatric medical care in Massachusetts with the aim of making those strategies available to pediatrics practices seeking to improve the care they provide.

Baystate Health's new Chief Research Officer, Peter Friedmann, MD, MPH, plans to strengthen research efforts and demonstrate the value of research to providers, patients and community.

New Chief Research Officer, Peter D. Friendmann, MD wants to strengthen Baystate's research programs to improve the health of patients and the community.

Dr. Sarah Goff, Department of Medicine, has received a highly competitive K23 research career development award from the National Institute of Child Health and Human Development.

Some are calling the potential of a new class of cholesterol-lowering drugs called PCSK9 inhibitors – now in trial at Baystate Medical Center and being debated by an advisory committee of the Food and Drug Administration, who will vote whether to recommend approval – as “one of the biggest developments in a long time in cardiology.”

The University of Massachusetts Medical School, Baystate Health, and the University of Massachusetts Amherst are planning to open a regional clinical campus of the medical school in Springfield. Students will begin enrolling in the 2017-18 academic year.

Known nationally as a leader in cardiovascular care, Baystate Medical Center was one of only 30 institutions in the U.S. and Europe invited to take part in an important Food and Drug Administration (FDA) trial.

Two Internal Medicine Residents' posters awarded prizes at state medical society meeting.